Filing Flows › Aurinia Pharmaceuticals (AUPH) › Net income
Aurinia Pharmaceuticals (AUPH) net income by quarter
Aurinia Pharmaceuticals' net income was $31.7M in Q3 2026 (third quarter 2026), -15% from Q2 2026. Over the last 7 quarters it ranged from $21.5M (Q2 2025) to $211M (Q4 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $31.7M | -15% | +0.5% |
| Q2 2026 | $37.4M | +9% | +74% |
| Q1 2026 | $34.4M | -84% | +47% |
| Q4 2025 | $211M | +568% | — |
| Q3 2025 | $31.6M | +47% | — |
| Q2 2025 | $21.5M | -8% | — |
| Q1 2025 | $23.3M | — | — |
Q3 2026 at a glance
Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%, net earnings $31.7M, operating cash flow $46.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Aurinia Pharmaceuticals' net income?
Aurinia Pharmaceuticals' net income was $31.7M in Q3 2026 (third quarter 2026), -15% from Q2 2026.
How has Aurinia Pharmaceuticals' net income changed?
Over the last 7 quarters it ranged from $21.5M (Q2 2025) to $211M (Q4 2025).
Q3 2026 results → · How Aurinia Pharmaceuticals makes money →